Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BHAV Acquisition agrees to combine with Nemi

BHAV Acquisition agrees to combine with Nemi

BitgetBitget2026/11/05 13:47
  • Nemi will go public through a combination with BHAV Acquisition at a $400 million pre-money equity value, entirely in stock.
  • The deal targets approximately $142.5 million in closing cash, assuming a full $50 million PIPE at $10 per share and no redemptions.
  • A $30 million minimum closing cash condition can be waived; the transaction includes no earnout.
  • Closing is expected in the first quarter of 2027, with Nemi's Class A common stock expected to trade on Nasdaq as NEMI.
  • Proceeds will fund manufacturing expansion, acquisitions and further development of Nemi's AI-powered manufacturing platform.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BHAV Acquisition Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050845PRIMZONEFULLFEED9870975) on November 05, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss